Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.
To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.
A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Start Date
January 1, 2002
Primary Completion Date
January 1, 2006
Completion Date
January 1, 2006
Last Updated
March 17, 2011
190
ACTUAL participants
Talampanel
DRUG
Placebo
DRUG
Talampanel
DRUG
Talampanel
DRUG
Placebo
DRUG
Talampanel
DRUG
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions